Homeopathic Recombinant Human Growth Hormone (hGH)

Chapter 8.2 from The Advanced Guide to Longevity Medicine Published by IMPAKT Communications 3/31/01
by Barbara Brewitt, Ph.D.

Recent randomized, double-blinded, placebo-controlled clinical studies demonstrated and replicated positive benefits of homeopathic recombinant human growth hormone (Brewitt et al. 1999). The three differently designed studies showed that an oral chewable tablet of homeopathic growth hormone was clinically efficacious, safe, non-toxic and economically practical as a longevity medicine. Functional benefits included those on the physical, physiological and psychological levels.

The body is challenged daily by a barrage of toxins and changing pathogens. Our sense of well being and survival are maintained via a highly regulated cell-to-cell communication network with the neuroimmunoendocrine system. It is adaptive and memory-specific to each person’s set of experiences. As the regulatory controls over cell-to-cell communication weaken, aging occurs. Restoration of these regulatory controls over cell signaling within the neuroimmunoendocrine system is key for health and quality of life.

Human growth hormone (hGH) is one of the powerful regulatory cell signaling neuropeptide/hormone/growth factors. It is well known for its direct effects on longevity and quality of life. While most hGH direct effects are generally attributed to the liver and the synthesis of insulin-like growth factor-1 (IGF-1), hGH has target signals to the Islets of Langerhans, intestines, skin, prostate, uterus, heart, brain, lungs, eyes and immune cells, all part of the neuroimmunoendocrine system. These organs also manifest early symptoms of aging. It has been postulated that the regulation and maintenance of information flow between the nervous, immune and endocrine systems are one method of influencing the aging process (Semsei 2000). Cell signaling molecules, such as hGH are shared between these three systems and we wanted to test if intervention with an oral homeopathic hGH would increase feedback between these systems, thus diminish common self-reported symptoms of aging.

Good biomarkers for aging include self-reported symptoms that impede the physical, psychological or emotional quality of life. Self-reported quality of life measures were evaluated in all three types of randomized, double-blinded, placebo-controlled studies conducted on homeopathic recombinant human growth hormone (HrhGH) (Brewitt et al. 1999). Healthy people ages 18-72 years of age were enrolled (n=162) for four to eight weeks in three different cities. Their exercise activity ranged from none to at least five times per week. In one city, no one knew the substance being evaluated. Blood chemistry, total weight, lean body mass and body shape measurements were objective parameters evaluated. Clinical efficacy was determined by statistical differences between chewable tablets of HrhGH and placebo that were self-administered three times/day.

Serum igf-1 levels

The study findings highlighted several significant observations relevant to longevity. First, baseline serum IGF-1 levels were, on average, lower than the mean average reference range in two of the three cities selected for study (P<0.0001). Neither age nor exercise lead to the normalization of serum IGF-1 levels, only HrHGH lead to normal raises in IGF-1. Three physicians who used exercise only to raise IGF-1 levels actually decreased by –28 ± 4% in their serum IGF-1 levels after the first 21 days of the study.

Oral administration of HrhGH reproducibly increased serum IGF-1 levels by +25 ± 14% after three weeks on a formula of 6X +12C and +21 ± 13% and +26 ± 10% on a formula of 6C + 100C +200C after three and four weeks, respectively. HrhGH was the single most important intervention raising serum-IGF-1 levels. Exercise without adequate nutrition decreased serum IGF-1 levels. While serum IGF-1 has been cited most as a reliable measure of hGH physiological activity, others do not include it as a reliable indicator (Ho and Veldhuis 1994)

Lean body mass

Maintenance of lean body mass is critical for longevity and quality of life functions since lean mass below 65% of ideal weight no longer supports life (Griffin et al. 1998). Lean mass includes muscle, bone, organ density, all of which deteriorate during the aging process and directly correlate with death. Lean body mass reproducibly increased 2.5 ± 1.2 lbs in three weeks on 6C +100C +200C HrhGH compared to no increase on placebo (P=0.05). Weight loss of -3.27 ± 0.6lbs occurred on the 6X +12C HrhGH formula and –2.07 ± 0.52 lbs occurred on the 6C + 100C +200C HrhGH formula compared to none on placebo (P<0.05). In addition to objectively measured gains in lean mass, subjects self-reported gains in arm and leg strength, endurance and appearance.

Substantiation of the body weight and lean mass changes occurred with measurable body shape changes. Upper arms, where lean mass is most observable, increased +0.30 ± 0.1 inch in three weeks compared to placebo (P<0.0001). Neither age nor gender affected this outcome, only HrhGH treatment. Hips, where fat mass is commonly observable, decreased –2.1 ± 0.50 inches/month on treatment compared to placebo (P<0.001).

Overall improvements

Twenty-five self-perceived symptoms were evaluated in all studies. HrhGH treatment groups showed significant improvements in those areas most specific to hGH target sites compared to placebo. For example, in terms of hormonal declines that affect hGH-target sites of skin, intestines, urogenital and lungs, subjects reported statistically significant improvements in terms of skin softness and moisture, easier breathing with less coughing and phlegm build-up, relief from intestinal pain and/or bloating. In terms of neurological and psychological improvements subject reported statistically significant relief from apathy, anxiety, anger, headaches, joint pain and/or edema. Sleep quality, length and depth also significantly improved.

Quality of life during aging means being able to complete the physical tasks necessary to carry out one’s functions. Subjects on HrhGH treatment reported statistically greater energy and endurance, increased libido and visual improvement compared to placebo. Thus, specific target sites for hGH in the body that can be self recognized for health symptoms such as lungs, skin, intestines, urogenital, heart function, eyes and brain were all reported as improved on homeopathic recombinant hGH versus placebo.

These short clinical studies demonstrate that intervention with a cell signaling treatment approach using oral chewable tablets of HrhGH provided statistically significant physiological and psychological benefits above placebo effects. While longer studies are necessary, the implications of these studies are that affordable and non-toxic options are available to people as preventative medicines.

Barbara Brewitt, Ph.D. is internationally recognized as a leader in scientific and clinical studies on homeopathic recombinant growth factors and growth hormone for healthy aging, longevity and models of rapid aging, such as HIV. Her visionary research integrates molecular biology of recombinant human growth hormone with the safety of homeopathy to optimize hormonal, nervous and immune functioning. Dr. Brewitt completed post-doctoral research on growth factors at the National Institutes of Health (NIH) after receiving a Ph.D. from the University of Washington School of Medicine, where she is now a Visiting Scientist.

Literature cited

Brewitt, B., Hughes, J., Welsh, E.A., Jackson, R. Homeopathic human growth hormone for physiologic and psychologic health. Alt. Compl. Ther. 1999 5(6):373-385

Griffin, G. E., Paton, N. I., Cofrancesco Jr., J., Arastéh, K., Bauer, G., Schwenk, A., Mauss, S., Mulligan, K. 1998 Nutrition and quality of life in HIV infection. The role of growth hormone in HIV-associated wasting. J. Clin. Res. 1:199-218

Ho, K.Y., Velduis, J.D. Diangosis of growth hormone deficiency in adults. Endocrinol. Metab. 1994 1(suppl. A):561-563

Semsei, I. On the nature of aging. Mech. Ageing Dev. 2000 117(1-3):93-108